Investors express both bullish and bearish sentiments regarding Regeneron Pharmaceuticals Inc. In a positive development, Dupixent®, Regeneron's drug, has been approved for use in young children with Eosinophilic Esophagitis in the EU. Regeneron's Q3 financial report beats expectations with strong Eylea HD and Dupixent sales. However, High-Dose Eylea, a chief revenue earner for the company, is underperforming and facing looming biosimilars. Several legal hurdles arise as Regeneron involved in a lawsuit regarding a patent dispute with COVID-19 treatment. Insider selling of shares by executives and significant stakeholders contribute to a bearish outlook. Analysts' divided viewpoints impact the stock, with Evercore suggesting an overreaction to the stock drop, while Leerink downgraded Regeneron’s rating over a negative Eylea injunction ruling. The company also faced a price target reduction from Oppenheimer. The future remains uncertain with investment whales betting on Regeneron while others are selling off shares quickly, creating a mixed market sentiment around REGN.
Regeneron Pharmaceuticals REGN News Analytics from Wed, 10 Apr 2024 07:00:00 GMT to Sat, 09 Nov 2024 13:36:12 GMT - Rating -2 - Innovation 4 - Information 4 - Rumor 2
